Literature DB >> 3339606

Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV).

T S Lin1, J Y Guo, R F Schinazi, C K Chu, J N Xiang, W H Prusoff.   

Abstract

Various 3'-azido analogues of pyrimidine deoxyribonucleosides have been synthesized and tested against human immunodeficiency virus (HIV-1, HTLV-III/LAV) in human peripheral blood mononuclear cells. Among these compounds, the 3'-azido analogues of thymidine (2), 3-(3-oxo-1-propenyl)thymidine (21), 2'-deoxyuridine (1), 2'-deoxy-5-bromouridine(5), 2'-deoxy-5-fluorocytidine (19), 2'-deoxy-5-iodouridine (6), 2'-deoxycytidine (18), 2'-deoxy-5-fluorouridine (4), 2'-deoxy-5-thiocyoanatouridine (16), 2'-deoxy-5-methylcytidine (20), 2'-deoxy-5-aminouridine (7), and 2'-deoxy-5-hydroxyuridine (10) were found to have significant antiviral activity, with EC50 values of 0.002, 0.01, 0.2, 1.0, 1.0, 1.1, 1.2, 4.8, 5.1, 5.1, 6.2, and 10 microM, respectively. The structure-activity relationships are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339606     DOI: 10.1021/jm00397a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Quantitative structure-activity relationships (QSARs) of pyrimidine nucleosides as HIV-1 antiviral agents.

Authors:  M Mahmoudian
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

2.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

3.  Predicting anti-HIV activity: computational approach using a novel topological descriptor.

Authors:  S Gupta; M Singh; A K Madan
Journal:  J Comput Aided Mol Des       Date:  2001-07       Impact factor: 3.686

4.  Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; J P Sommadossi; V Saalmann; D L Cannon; M Y Xie; G C Hart; G A Smith; E F Hahn
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1.

Authors:  Michael J Dapp; Laurent Bonnac; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Synthesis and antimicrobial evaluation of 5-iodopyrimidine analogs.

Authors:  N M Goudgaon; N J Basha; S B Patil
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

8.  Correlation between preferred sugar ring conformation and activity of nucleoside analogues against human immunodeficiency virus.

Authors:  P Van Roey; J M Salerno; C K Chu; R F Schinazi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  R F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; M St Clair; J Wilson; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.

Authors:  Joy Y Feng; Eisuke Murakami; Suzana M Zorca; Allison A Johnson; Kenneth A Johnson; Raymond F Schinazi; Phillip A Furman; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.